Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
No patients were enrolled
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to validate Whole Genome Sequencing (WGS) on amniotic fluid to reduce the time to diagnosis and enhance the care for the fetus/neonate.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Validation of Rapid Whole Genome Sequencing technology on amniotic fluid samples | Collection of both amniotic fluid and blood samples to compare results of whole genome sequencing for a fetus with suspected genetic disease. | 5 years |
| Enrollment of study participants | To recruit up to 90 total participants including child and both parents | 5 years |
| Collection of Biospecimens | Total number of biospecimens collected which may include both blood samples and amniotic fluid | 5 years |
Not provided
Not provided
Inclusion Criteria
Exclusion Criteria
Not provided
Not provided
Not provided
Not provided
Participants will be identified internally through provider referrals most commonly through the Mayo Clinic Obstetrical and Maternal Fetal Medicine services.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Myra Wick, MD, PhD | Mayo Clinic | Principal Investigator |
Not provided
Not provided
| Label | URL |
|---|---|
| Mayo Clinic Clinical Trials | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided